ENHANCED EFFICACY ASSOCIATED WITH EARLY TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB SODIUM
| Autor: | Christine R. Gonzales |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Visual acuity genetic structures Pegaptanib Oligonucleotides Visual Acuity law.invention Macular Degeneration Double-Blind Method Randomized controlled trial law Ophthalmology medicine Pegaptanib Sodium Humans Fluorescein Angiography Aged Retrospective Studies Aged 80 and over medicine.diagnostic_test business.industry General Medicine Aptamers Nucleotide Middle Aged Macular degeneration medicine.disease Fluorescein angiography Choroidal Neovascularization eye diseases Clinical trial Treatment Outcome Choroidal neovascularization Female sense organs medicine.symptom business medicine.drug |
| Zdroj: | Retina. 25:815-827 |
| ISSN: | 0275-004X |
| DOI: | 10.1097/00006982-200510000-00001 |
| Popis: | To assess the vision benefit of treating early subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) with pegaptanib sodium.Exploratory analyses of week 54 vision outcomes (VEGF Inhibition Study in Ocular Neovascularization study) of subject subgroups with early disease who received 0.3 mg of pegaptanib (Groups 1 [n = 34] and 2 [n = 30]) or sham injections (usual care). Two sets of clinical characteristics typical of early disease defined the subgroups.Baseline characteristics were generally well balanced between treatment arms. Pegaptanib responder rates (loss of15 letters of visual acuity) were 76% and 80% in treatment Groups 1 and 2 versus 50% and 57% for usual care Groups 1 and 2 (P = 0.03 and P = 0.05), respectively. Compared with subjects assigned to pegaptanib, those in Groups 1 and 2 receiving usual care on average lost 11.1 letters and 12.7 letters more of visual acuity (P0.01 and P0.006), respectively. Subjects assigned to usual care were approximately 10 times more likely to have severe vision loss than were those treated with pegaptanib (Group 1, 29% vs. 3%, respectively; P0.01). In Group 1, 12% of pegaptanib-treated subjects gainedor =15 letters of visual acuity versus 4% receiving usual care; 20% of Group 2 pegaptanib-treated subjects gainedor =15 letters of visual acuity versus none of the usual care subjects.Early detection and treatment with pegaptanib may result in superior vision outcomes in patients with neovascular AMD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|